The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study - 02/03/21
, Christopher M Jones, MRCP a, b, c, Rebecca Girdler, PGCE d, Catherine Roe, MSc d, Michael Sharpe, BSc d, Sarah Lawton, MPH d, Louise Miller, MA d, Philippa Lewis, FRCR e, f, Mererid Evans, PhD g, David Sebag-Montefiore, ProfFRCR a, c, Tom Roques, FRCR f, h, Rebecca Smittenaar, PhD d, Eva Morris, ProfPhD i
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Summary |
Background |
The indirect impact of the COVID-19 pandemic on cancer outcomes is of increasing concern. However, the extent to which key treatment modalities have been affected is unclear. We aimed to assess the impact of the pandemic on radiotherapy activity in England.
Methods |
In this population-based study, data relating to all radiotherapy delivered for cancer in the English NHS, between Feb 4, 2019, and June 28, 2020, were extracted from the National Radiotherapy Dataset. Changes in mean weekly radiotherapy courses, attendances (reflecting fractions), and fractionation patterns following the start of the UK lockdown were compared with corresponding months in 2019 overall, for specific diagnoses, and across age groups. The significance of changes in radiotherapy activity during lockdown was examined using interrupted time-series (ITS) analysis.
Findings |
In 2020, mean weekly radiotherapy courses fell by 19·9% in April, 6·2% in May, and 11·6% in June compared with corresponding months in 2019. A relatively greater fall was observed for attendances (29·1% in April, 31·4% in May, and 31·5% in June). These changes were significant on ITS analysis (p<0·0001). A greater reduction in treatment courses between 2019 and 2020 was seen for patients aged 70 years or older compared with those aged younger than 70 years (34·4% vs 7·3% in April). By diagnosis, the largest reduction from 2019 to 2020 in treatment courses was for prostate cancer (77·0% in April) and non-melanoma skin cancer (72·4% in April). Conversely, radiotherapy courses in April, 2020, compared with April, 2019, increased by 41·2% in oesophageal cancer, 64·2% in bladder cancer, and 36·3% in rectal cancer. Increased use of ultra-hypofractionated (26 Gy in five fractions) breast radiotherapy as a percentage of all courses (0·2% in April, 2019, to 60·6% in April, 2020; ITS p<0·0001) contributed to the substantial reduction in attendances.
Interpretation |
Radiotherapy activity fell significantly, but use of hypofractionated regimens rapidly increased in the English NHS during the first peak of the COVID-19 pandemic. An increase in treatments for some cancers suggests that radiotherapy compensated for reduced surgical activity. These data will assist health-care providers in understanding the indirect consequences of the pandemic and the role of radiotherapy services in minimising these consequences.
Funding |
None.
El texto completo de este artículo está disponible en PDF.Esquema
Vol 22 - N° 3
P. 309-320 - mars 2021 Regresar al número
Artículo precedente
- From periwinkle to an enduring anticancer drug
- Guy Faguet
- High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
- Bjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten, Odd Terje Brustugun, Kjersti Hornslien, Tesfaye Madebo, Seppo Wang Langer, Tine Schytte, Jan Nyman, Signe Risum, Georgios Tsakonas, Jens Engleson, Tarje Onsøien Halvorsen
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.